State Street’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

State Street’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-91,850	Closed	-$16K	–	4971
2022 Q3	$16K	Hold	91,850	–	–	﹤0.01%	4857
2022 Q2	$55K	Buy	91,850 +4,000	+5%	+$3.83K	﹤0.01%	4706
2022 Q1	$116K	Buy	87,850 +8,772	+11%	+$14.2K	﹤0.01%	4600
2021 Q4	$206K	Hold	79,078	–	–	﹤0.01%	4336
2021 Q3	$246K	Hold	79,078	–	–	﹤0.01%	4284
2021 Q2	$294K	Sell	79,078 -265,579	-77%	-$884K	﹤0.01%	4059
2021 Q1	$1.19M	Buy	344,657 +66,700	+24%	+$271K	﹤0.01%	3582
2020 Q4	$934K	Sell	277,957 -22,800	-8%	-$81.6K	﹤0.01%	3563
2020 Q3	$1.06M	Buy	300,757 +42,674	+17%	+$172K	﹤0.01%	3416
2020 Q2	$1.19M	Buy	258,083 +8,773	+4%	+$38.9K	﹤0.01%	3373
2020 Q1	$825K	Buy	249,310 +19,531	+8%	+$89.4K	﹤0.01%	3351
2019 Q4	$1.4M	Buy	229,779 +8,537	+4%	+$35.2K	﹤0.01%	3350
2019 Q3	$923K	Buy	221,242 +31,568	+17%	+$252K	﹤0.01%	3415
2019 Q2	$1.57M	Buy	+189,674	New	+$2.32M	﹤0.01%	3327

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street's PHAS Position: Q4 2022 in Review

State Street sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 91,850 shares — an estimated $16K sold.

State Street first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $1.57M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

State Street reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
State Street sold 91,850 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $16K.
State Street first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
State Street's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.57M in Q2 2019.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.